Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
1988-8-31
|
pubmed:abstractText |
This study showed that a mAb (145-2C11) against the T3 epsilon-chain of the TCR complex augmented the cytotoxic activity of the lymphokine-activated killer (LAK) effectors. The LAK cells were induced by culturing normal spleen cells with purified human rIL-2. Adding alpha T3 at the effector phase of the cytotoxic reactions augmented the LAK-mediated cytotoxicity. The alpha T3-augmented LAK killing was seen only with tumor targets, and there was no increase of killing against Con A-induced lymphoblasts. The augmentation effect was dose dependent on both the amounts of alpha T3 and the number of LAK cells added. A very low concentration of alpha T3 (1/10,000 dilution of culture supernatants) was sufficient to induce alpha T3-augmented LAK-mediated cytotoxicity. Human rIL-2 at 10 to 30 U/ml was sufficient to generate LAK cells for maximal alpha T3 augmentation, whereas 300 to 1000 U/ml of IL-2 were needed to generate maximal LAK activity when tested in the absence of alpha T3. LAK cells generated for longer periods of time showed a progressive increase of alpha T3-augmented cytotoxicity. For some targets, the alpha T3-augmented LAK killing was FcR dependent as evidenced by the ability of alpha FcR mAb 2.4G2 to inhibit, and for others it was not inhibited. The alpha T3-augmented killing did not correlate with the FcR expression on target cells as defined by 2.4G2. The LAK cells were both Lyt-2+ and Lyt-2-, but the LAK cells involved in alpha T3-augmented killing were exclusively Lyt-2+. Preincubation of LAK cells with alpha T3, but not preincubation of targets with alpha T3, resulted in augmented killing suggesting that the alpha T3 effect was unrelated to an antibody-dependent cell-mediated cytotoxicity. Our findings indicate that alpha T3 is a potent reagent to augment the cytotoxic reaction of LAK cells. These results suggested that a relationship might exist between the T3 complex and the cytotoxic activity of a subpopulation of Lyt-2+ LAK cells.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Adjuvants, Immunologic,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, Differentiation...,
http://linkedlifedata.com/resource/pubmed/chemical/Lymphokines,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Fc
|
pubmed:status |
MEDLINE
|
pubmed:month |
Aug
|
pubmed:issn |
0022-1767
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
1
|
pubmed:volume |
141
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
741-8
|
pubmed:dateRevised |
2011-11-17
|
pubmed:meshHeading |
pubmed-meshheading:3260909-Adjuvants, Immunologic,
pubmed-meshheading:3260909-Animals,
pubmed-meshheading:3260909-Antibodies, Monoclonal,
pubmed-meshheading:3260909-Antigens, Differentiation, T-Lymphocyte,
pubmed-meshheading:3260909-Binding, Competitive,
pubmed-meshheading:3260909-Binding Sites, Antibody,
pubmed-meshheading:3260909-Cell Line,
pubmed-meshheading:3260909-Cytotoxicity, Immunologic,
pubmed-meshheading:3260909-Dose-Response Relationship, Immunologic,
pubmed-meshheading:3260909-Female,
pubmed-meshheading:3260909-Killer Cells, Natural,
pubmed-meshheading:3260909-Lymphocyte Activation,
pubmed-meshheading:3260909-Lymphokines,
pubmed-meshheading:3260909-Mice,
pubmed-meshheading:3260909-Mice, Inbred C57BL,
pubmed-meshheading:3260909-Mice, Inbred DBA,
pubmed-meshheading:3260909-Phenotype,
pubmed-meshheading:3260909-Receptors, Fc,
pubmed-meshheading:3260909-Spleen,
pubmed-meshheading:3260909-Time Factors
|
pubmed:year |
1988
|
pubmed:articleTitle |
Augmentation by anti-T3 antibody of the lymphokine-activated killer cell-mediated cytotoxicity.
|
pubmed:affiliation |
Experimental Immunology Branch, National Cancer Institute, Bethesda, MD 20892.
|
pubmed:publicationType |
Journal Article
|